school for phlebotomy phlebotomist training california phlebotomy school
Wednesday, 4 April 2012
Recent advances in the pathophysiology and pharmacological treatment of obesity
Conclusion:? Despite recent setbacks in the pharmacotherapy of obesity (withdrawal of rimonabant and sibutramine), many compounds are in phase II/III trials. The future holds promise for a new drug that alone or in combination with an existing agent could target the initial pathophysiology and morbidities associated with obesity. (Source: Journal of Clinical Pharmacy and Therapeutics)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment